Chief Executive Officer & President
Richard Hague is an accomplished senior biotechnology executive with broad leadership experience in both private and public companies. Before joining PolarityTE, Richard was Chief Commercial Officer at Anika Therapeutics, where he led all global commercial activities and had oversight of the clinical operations and R&D functions for Anika’s hyaluronic acid based technology platform used in orthopedics, wound care and ophthalmology. Prior to his tenure with Anika, Richard was Vice President of Sales and Marketing at TEI Medical, where he led the build out of those functions resulting in significant growth of their acellular collagen matrix for the management of complex wounds, which ultimately led to Integra’s acquisition of TEI. Richard spent a significant portion of his career at Genzyme and later Sanofi (post Sanofi’s acquisition of Genzyme) where he held positions of increasing responsibility, culminating in his role as VP/General Manager of Sanofi’s Cell Therapy and Regenerative Medicine Business Unit. While at Genzyme, Richard played an integral role in the launch and adoption of the first autologous cell therapy products used in orthopedics and burns. Subsequently, he has led the development and launch of innovative products in multiple markets via the CBER and CDRH regulatory pathways.